A Phase III, Open-label, Multi-centre Study to Assess the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Live Attenuated Varicella Vaccine (VarilrixTM), Given as a Primary Vaccination at 4.5 Months and 6.5 Months Post-transplantation, in Autologous Stem Cell/ Bone Marrow Transplant Recipients Aged 18 Years and Older.
Phase of Trial: Phase II
Latest Information Update: 10 Jul 2017
At a glance
- Drugs Varicella zoster virus vaccine live (Primary)
- Indications Herpes zoster
- Focus Adverse reactions; Pharmacodynamics
- Sponsors GlaxoSmithKline
- 29 Nov 2008 New trial record.